Skip to main content

Table 3 Association of tumor GFRα1, GFRα3 and SDC3 protein expression with clinicopathologic parameters of patients with mammary carcinoma

From: Prognostic significance of the expression of GFRα1, GFRα3 and Syndecan-3, proteins binding ARTEMIN, in mammary carcinoma

  GFRα1 expression (n (%)) GFRα3 expression (n (%)) SDC3 expression (n (%))
Parameter n protein P protein P protein P
Age (years)
≤ 35 16 9 (56.3) 0.249 9 (56.3) 0.078 5 (31.3) 0.768
35-55 92 34 (37.0)   26 (28.3)   24 (26.1)  
> 55 51 17 (33.3)   15 (29.4)   16 (31.4)  
Tumor size (cm)
≤ 2 13 6 (46.2) 0.135 4 (30.8) 0.37 5 (38.5) 0.555
2 ~ 5 115 38 (33.0)   33 (28.7)   30 (26.1)  
> 5 31 16 (51.6)   13 (41.9)   10 (32.3)  
Histologic type
Ductal 150 57 (38.0) 0.142 49 (32.7) 0.352 41 (27.3) 0.313
Lobular 6 2 (33.3)   1 (16.7)   2 (33.3)  
Mucinous 3 1 (33.3)   0 (0)   2 (66.7)  
Lymph node metastasis
0 55 9 (16.4) 0.001 9 (16.4) 0.006 15 (27.3) 0.977
1 ~ 3 55 24 (43.6)   19 (34.5)   16 (29.1)  
>3 49 27 (55.1)   22 (44.9)   14 (28.6)  
Grade
I 13 6 (46.2) 0.657 4 (30.8) 0.906 4 (30.8) 0.788
II 102 36 (35.2)   31 (30.4)   27 (26.5)  
III 44 18 (40.9)   15 (34.1)   14 (31.8)  
Stage
I-II 85 19 (22.4) 0.001 19 (22.4) 0.008 23 (27.1) 0.709
III-IV 74 41 (55.4)   31 (41.9)   22 (29.7)  
ER status^
- 94 39 (41.5) 0.24 27 (28.7) 0.374 24 (25.5) 0.351
+ 65 21 (32.3)   23 (35.4)   21 (32.3)  
PR status^^
- 90 32 (35.6) 0.517 28 (31.1) 0.917 22 (24.4) 0.218
+ 69 28 (40.6)   22 (31.9)   23 (33.3)  
HER-2 *
- 121 40 (33.1) 0.03 31 (25.6) 0.005 33 (27.3) 0.607
+ 38 20 (52.6)   19 (50.0)   12 (31.6)  
  1. ^ ER positive required at least 10% staining nuclei.
  2. ^^ PR positive required at least 10% staining nuclei.
  3. HER-2 positive were 3+ or 2+ and FISH confirmed.
  4. Values in bold are significant (P < 0.05).